Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko Sells 53,001 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 53,001 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $12.05, for a total value of $638,662.05. Following the transaction, the chief executive officer owned 568,880 shares in the company, valued at approximately $6,855,004. This represents a 8.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jacob Chacko also recently made the following trade(s):

• On Tuesday, September 30th, Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.01, for a total value of $414,801.38.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.80, for a total value of $1,350,000.00.

Oric Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $11.32 on Friday. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67. The business’s 50-day simple moving average is $10.39 and its 200 day simple moving average is $8.49. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -5.99 and a beta of 1.68.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). On average, equities research analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Analyst Upgrades and Downgrades

ORIC has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. JPMorgan Chase & Co. cut their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, August 14th. Guggenheim started coverage on Oric Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $18.00 price target on the stock. Zacks Research raised Oric Pharmaceuticals to a “hold” rating in a report on Tuesday, August 12th. Finally, LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a “buy” rating and a $15.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.29.

Institutional Trading of Oric Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Oric Pharmaceuticals by 2.9% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock worth $497,000 after buying an additional 1,358 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Oric Pharmaceuticals by 35.9% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock worth $53,000 after buying an additional 1,372 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Oric Pharmaceuticals by 17,300.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock worth $25,000 after buying an additional 2,422 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Oric Pharmaceuticals by 7.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company’s stock worth $394,000 after buying an additional 2,706 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after buying an additional 3,131 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.